[{"arm_notes": "", "treatment_id": null, "treatment_name": "TODO Treatment - DrugsIntervention group: After eligibility assessment of the patient and enrollment patients will be randomly assign to receive anakinra 100mg intravenous daily for 14 days as an adjunctive treatment to the latest recommended pharmacotherapy of national guideline for treatment of COVID-19. the medication will be administered intravenously by a trained staff.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "TODO Treatment - DrugsControl group: After eligibility assessment of the patient and enrollment patients will be randomly assign to the control group. patients in control group will receive medical treatment of COVID-19 based on latest national protocol only.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": 83, "treatment_name": "Anakinra", "treatment_type": "Interleukin inhibitors", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}]